ACAndrew Chou

Andrew Chou

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Andrew Chou has a total of 34 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Evaluating antibiotic prescriptions and standardized surveillance definitions among infections in home-based primary care

    by Duc Nguyen, Maura Singh, Andrew Chou, Rupak Datta

    Between 2023 – 2024, 60 infections (urinary tract, n = 31; skin/soft tissue, n = 18; pneumonia, n = 7; influenza-like illness, n = 5) were diagnosed by home-based primary care clinicians from one site, including 35% through telehealth. 43% met standardized surveillance definitions. Most antibiotic prescriptions ( n = 27/48) involved durations ≥7 days. Additional studies of home care infections are needed.

  • Isavuconazole provides effective and tolerable antifungal prophylaxis for patients with acute myeloid leukemia

    by Cameron J. Hunter, Andrew Chou, Heidi Roeder, William Eighmy, Jan Philipp Bewersdorf, Lourdes Mendez, Maximilian Stahl, Nikolai A. Podoltsev, Amer M. Zeidan, Rory M. Shallis


  • Open Access

    Extracting antibiotic susceptibility from free-text microbiology reports using natural language processing

    by Andrew Chou, Ronald George Hauser, Lori A. Bastian, Cynthia A. Brandt, Barbara W. Trautner

    There is a clinical need to appropriately apply large language model (LLM)-based systems for use in infectious diseases. We sought to use LLM and machine learning for extracting antibiotic susceptibility from clinical microbiology free-text reports, allowing use for outbreak detection, increasing information gathering efficiency, and public health reporting.


  • Open Access

    715. Dynamic gain and loss of carbapenem-resistant Enterobacterales by VHA patients during 2016-2022: loss of CRE exceeds gain of CRE

    by Andrew Chou, David J Ramsey, Barbara Trautner

    Carbapenem-resistant Enterobacterales (CRE) are an important public health threat. The long-term prognosis and duration that patients harbor CRE is not well described. Identification of eligibility Sankey diagram shows dynamic CRE status changes over time Risk for CRE+ culture after index CRE culture (time 0) CRE+ culture gain & loss dynamics over time N: no bacterial cultures; S: cultures without CRE; R: cultures with CRE. Percentages are the number of subjects that changed status divided by total at prior state. For example N to R: 42 (4%) means 42 subjects changed from N to R status during the time period. 4% represented the 42 subjects that changed status were out of 1,011 that started the time period in N status (42/1011 = 4%). After an index CRE culture, subjects steadily changed from R status (grew CRE during time period) to S status (grew non-CRE during time period) at the rate of 30% to 36% per year. After subjects converted to S status (grew non-CRE during time period), the rate of reversion to R status (grew CRE during time period) was 2% to 6% per year. Andrew Chou, MD, MSc, Entasis Therapeutics: Stocks/Bonds Barbara Trautner, MD, PhD, Genentech: Grant/Research Support|Peptilogics: Grant/Research Support

  • Open Access

    Quantifying the Implementation and Cost of a Multisite Antibiotic Stewardship Intervention for Asymptomatic Bacteriuria

    by Eva Amenta, Larissa Grigoryan, Suja S. Rajan, David Ramsey, Jennifer R. Kramer, Annette Walder, Andrew Chou, John N. Van, Sarah L. Krein, Sylvia Hysong, et al.

    Objective: The intensity of an antibiotic stewardship intervention to achieve clinical impact is not known. We conducted a multisite dissemination project of an intervention to reduce treatment of asymptomatic bacteriuria (ASB) and studied: (1) the association between implementation metrics and clinical outcomes and (2) the cost of implementation. Design/Setting/Participants: A central site facilitated a multimodality intervention to decrease unnecessary urine cultures and antibiotic treatment in patients with ASB at 4 Veterans Affairs medical centers. Methods: The intervention consisted of a decision support aid algorithm and interactive teaching cases that provided in the moment audit and feedback on how to manage ASB. Implementation outcomes included minutes spent in intervention delivery, number of healthcare professionals reached, and number of sessions delivered. Clinical outcomes included days of antibiotic therapy (DOT), length of antibiotic therapy (LOT), and number of urine cultures ordered per 1000 bed days. Personnel reported weekly time logs. Results: Minutes spent in intervention delivery were inversely correlated with two clinical outcomes, DOT (R −0.3, P = .04) and LOT (R −0.3, P = .02). Number of healthcare professionals reached and number of sessions delivered were not correlated with clinical outcomes of DOT (R –0.003, P = .98, R = −0.059, P = .69) or LOT (R +0.073, P = .62, R −0.102, P = .49). Physician champions spent an average of 3.8% of effort on the intervention. The implementation cost was USD 22,299/year per site on average. Conclusions: The amount of time local teams spent in delivery of an antibiotic stewardship intervention was correlated with the desired decrease in antibiotic use. Implementing this successful antibiotic stewardship intervention required minimal time.


  • Open Access

    Real-world experience with cefiderocol therapy for Pseudomonas aeruginosa and other multidrug resistant gram-negative infections within the Veterans Health Administration, 2019–2022

    by Andrew Chou, David Ramsey, Eva Amenta, Barbara W. Trautner

    Objective: Single-center and regional studies have reported outcomes after treatment with cefiderocol, a novel siderophore cephalosporin. We report on real-world use, clinical outcomes, and microbiological outcomes with cefiderocol therapy within the Veterans’ Health Administration (VHA). Design: Prospective, observational descriptive study. Setting: Veterans’ Health Administration, 132 sites across the United States, during 2019–2022. Patients: This study included patients admitted to any VHA medical center who received cefiderocol for ≥2 days. Methods: Data were obtained from the VHA Corporate Data Warehouse and through manual chart review. We extracted clinical and microbiologic characteristics and outcomes. Results: In total, 8,763,652 patients received 1,142,940,842 prescriptions during the study period. Of these, 48 unique individuals received cefiderocol. The median age of this cohort was 70.5 years (IQR, 60.5–74), and the median Charlson comorbidity score was 6 (IQR, 3–9). The most common infectious syndromes were lower respiratory tract infection in 23 patients (47.9%) and urinary tract infection in 14 patients (29.2%). The most common pathogen cultured was P. aeruginosa in 30 patients (62.5%). The clinical failure rate was 35.4% (17 of 48), and 15 (88.2%) of these 17 patients died within 3 days of clinical failure. The 30-day and 90-day all-cause mortality rates were 27.1% (13 of 48) and 45.8% (22 of 48), respectively. The 30-day and 90-day microbiologic failure rates were 29.2% (14 of 48) and 41.7% (20 of 48), respectively. Conclusions: In this nationwide VHA cohort clinical and microbiologic failure occurred in >30% of patients treated with cefiderocol, and >40% of these died within 90 days. Cefiderocol is not widely used, and many of the patients who received it had substantial comorbidities.


  • Open Access

    349Surveillance of Carbapenem Resistance and the First Case of NDM-7-producing Klebsiella pneumoniae in the Philippines

    by Andrew Chou, Michael Evangelista, Arielle Kae Sulit, Brian Torres, Marylette Roa, David C. Klinzing, Lynn Zechiedrich

    Background. KPC, NDM, and OXA-48 have spread to virtually every continent, although not every country has been affected. The SMART worldwide surveillance program from 2008-2009 characterized the molecular epidemiology of carbapenem resistant Klebsiella pneumoniae, and identified three K. pneumoniae ST903 with IMP-26 in the Philippines; no other carbapenemases have been reported in the Philippines.